Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | CCND3 | P30281 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740321 | 1.00 | CYP3A4 (0.51) | CYP3A4CYP2C9TRPM8SRCAAK1 | |
| SCHEMBL3751842 | 0.88 | CYP3A4 (0.57) | CYP3A4CYP2C9TRPM8CHEK1 | |
| SCHEMBL2771294 | 0.88 | CYP3A4 (0.57) | CYP3A4CYP2C9TRPM8CHEK1 | |
| SCHEMBL3750520 | 0.83 | CYP3A4 (0.54) | CYP3A4CYP2C9TRPM8TYK2 | |
| SCHEMBL2773346 | 0.83 | CYP3A4 (0.54) | CYP3A4CYP2C9TRPM8TYK2 | |
| SCHEMBL3740562 | 0.79 | TRPM8 (0.67) | CYP3A4CYP2C9TRPM8 | |
| SCHEMBL2771210 | 0.79 | CYP3A4 (0.48) | CYP3A4CYP2C9TRPM8SRC | |
| SCHEMBL3740565 | 0.79 | TRPM8 (0.67) | CYP3A4CYP2C9TRPM8 | |
| SCHEMBL3756066 | 0.79 | CYP3A4 (0.48) | CYP3A4CYP2C9TRPM8SRC | |
| SCHEMBL3750768 | 0.79 | CYP3A4 (0.63) | CYP3A4CYP2C9TRPM8PTPN1SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217060-B2 | Benzimidazole derivatives useful as TRP M8 receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-07-10 | — | — | US | claimed |
| WO-2010132247-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | claimed |
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-18 | — | — | US | claimed |
| US-8217060-B2 | Benzimidazole derivatives useful as TRP M8 receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-07-10 | — | — | US | disclosed |
| WO-2010132247-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | CYP3A4 2735/4885CYP2C9 2805/4885TRPM8 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.